News
Clinical Trials Arena on MSN7h
FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGSThe US Food and Drug Administration (FDA) has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback